A new class of non-opioid drugs treats pain by blocking signals before they reach the brain, reducing the risk of addiction.

Suzetrigine (Journavx) is the first new drug approved to treat acute pain in over 20 years and the first to be classified as ...

Recent developments, however, suggest that strategies to treat pain are starting to match its complexity with a new sophistication. The management of chronic pain in general is now being broadly ...

Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) shares are trading higher Friday following two major developments that strengthen ...

Other research has shown red light therapy could minimize the appearance of wrinkles, hyperpigmentation, and broken blood ...

After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...

People undergoing hemodialysis treatment for kidney failure often experience chronic pain related to their condition, but it ...

Suzetrigine, to be sold under the brand name Journavx, is the first new type of pain medicine approved by the FDA in more ...

The FDA has approved Journavx, an oral medication for treating pain that doesn't target the brain like addictive opioids.

Despite advances, there remain gaps in the understanding of and personalized treatment for chronic pain in rheumatology, especially among women.

The U.S. Food and Drug Administration has approved Journavx (suzetrigine) 50 milligram oral tablets, marking the introduction ...

The US Food and Drug Administration has approved a new, nonopioid pain medication for treating moderate to severe acute pain.